首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1274335

子宮內膜異位症治療全球市場研究報告——2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Endometriosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年05月01日 | 出版商:

Value Market Research | 英文 210 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

在 2023-2030 研究期間，全球對子宮內膜異位症治療市場的需求將以 25.62% 的複合年增長率增長，從 2022 年的 54.4 億美元增長到 2030 年的近 337.3 億美元，預計將達到

子宮內膜異位症是一種痛苦的婦科疾病，類似於子宮內膜的組織開始在腹部和骨盆的其他部位生長。子宮內膜異位症可發生在輸卵管、陰道、腸、直腸、隔膜、膀胱和輸尿管，以及子宮外和子宮後。症狀包括月經期間劇烈疼痛、痙攣、性交疼痛、月經期間大量出血、排便疼痛和月經期間腹痛。給予止痛藥和激素治療以緩解子宮內膜異位症的症狀。治療子宮內膜異位症的手術選擇包括腹腔鏡檢查和子宮切除術。

市場動態：

由於病例數的增加和對子宮內膜異位症治療需求的增長，對子宮內膜異位症治療市場的需求正在擴大。一些國家已經實施了政府舉措和宣傳計劃，以提高公眾對這種疾病的認識，導致對該市場的需求激增。此外，與發現更好的治療方法相關的越來越多的研發活動正在推動對該市場的需求。針對昂貴藥物的患者援助計劃正在增加對該市場的需求。此外，增加對醫療保健行業的投資以提供更好的治療設施正在推動該市場的增長。相反，子宮內膜異位症的非侵入性診斷測試不可用可能會阻礙子宮內膜異位症治療市場的增長。

研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還對全球子宮內膜異位症治療市場的每個細分市場進行了全面評估。子宮內膜異位症藥物行業的發展和趨勢為這項研究提供了一個整體的方法。

市場細分：

子宮內膜異位症治療市場報告的這一部分提供了有關國家和地區層面細分市場的詳細數據，從而幫助戰略制定者確定目標受眾和他們各自產品或服務的即將到來的機會。以支持

按治療類型

止痛藥
激素療法

按藥物類別

非甾體抗炎藥
口服避孕藥
促性腺激素釋放激素
其他

按給藥途徑

口語
注射
其他

按銷售渠道

醫院藥房
零售店
其他

按地區分析：

本節介紹了區域前景，重點關注北美、歐洲、亞太地區、拉丁美洲、中東和非洲子宮內膜異位症治療市場當前和未來的需求。此外，我們還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。子宮內膜異位症治療市場的主要參與者是拜耳公司、輝瑞公司、艾伯維公司、阿斯利康公司、ObsEva SA、Teva Pharmaceutical Industries、Zydus Healthcare Limited、Eli Lilly and Company、Astellas Pharma Inc。本節包括主要併購，它由全面的競爭格局的觀點，包括各種戰略發展，如未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

本報告的內容
- 目的
- 目標受眾
- 獨特的銷售建議 (USP) 和提供的服務
調查範圍
調查方法
- 市場調研過程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第三章子宮內膜異位症治療-行業分析

簡介 - 市場動態
市場驅動因素
市場製約因素
市場機會
行業趨勢
波特的五力分析
市場吸引力分析
- 按治療類型進行的市場吸引力分析
- 按藥物類別進行的市場吸引力分析
- 按給藥途徑進行的市場吸引力分析
- 按分銷渠道進行的市場吸引力分析
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商列表
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章按治療類型分列的全球子宮內膜異位症治療市場分析

治療類型概述
實際數據和預測數據
按治療類型分析
止痛藥
激素療法

第 7 章子宮內膜異位症治療的全球市場分析：按藥物分類

按藥物類別匯總
實際數據和預測數據
按藥物類別分析
非甾體抗炎藥
口服避孕藥
促性腺激素釋放激素
其他

第 8 章子宮內膜異位症藥物給藥途徑的全球市場分析

按給藥途徑匯總
實際數據和預測數據
給藥途徑分析
口服劑
注射
其他

第 9 章子宮內膜異位症藥物分銷渠道的全球市場分析

按分銷渠道概述
實際數據和預測數據
按分銷渠道分析
醫院藥房
零售藥房
其他

第 10 章子宮內膜異位症藥物的全球市場分析：按地區

區域展望
簡介
北美銷售分析
- 概覽、歷史和預測銷售分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測銷售分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、歷史和未來銷售分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 在中國的銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和未來銷售分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、歷史和未來銷售分析
- 中東/非洲地區的銷售分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第11章子宮內膜異位症藥物企業競爭狀況

子宮內膜異位症藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第12章公司簡介

頂級公司的市場份額分析
市場集中度
拜耳公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期發展狀況
輝瑞公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
艾伯維公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
阿斯利康
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Obs Eva SA
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Teva 製藥工業
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Zydus 醫療保健有限公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
禮來公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
安斯泰來製藥公司
- 公司簡介
- 企業收入
- 產品信息
- 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

簡介目錄圖表

Product Code: VMR112110345

The global demand for Endometriosis Treatment Market is presumed to reach the market size of nearly USD 33.73 BN by 2030 from USD 5.44 BN in 2022 with a CAGR of 25.62% under the study period 2023 - 2030.

Endometriosis is a painful gynaecological disorder in which endometrial-like tissues start growing in other parts of the abdomen and pelvic areas. Some places where endometriosis can develop are the fallopian tubes, vagina, intestine, rectum, diaphragm, bladder and ureter, outside and back of the uterus etc. Its symptoms may include heavy pain during menstruation, cramps, pain during sex, heavy bleeding during periods, painful bowel movements, abdominal pain during periods and others. Pain medications and hormone therapy are used to reduce the symptoms of endometriosis. The surgical options for the treatment of endometriosis are laparoscopy as well as hysterectomy.

Market Dynamics:

The demand for the endometriosis treatment market is scaling up due to the rising number of cases and the growing need for treatment of endometriosis. Government initiative and awareness programs across several countries to create awareness regarding this disease among people is surging the demand for this market. Moreover, the rise in research and development activities associated with discovering better treatment options propels the demand for this market. Patient assistance programs for expensive drugs are augmenting the demand for this market. Furthermore, growing investment in healthcare sectors to provide better treatment facilities is boosting the growth of this market. Conversely, the unavailability of non-invasive diagnostic tests for endometriosis may obstruct the growth of the endometriosis treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of endometriosis treatment. The growth and trends of endometriosis treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the endometriosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

Pain Medication
Hormone Therapy

By Drug Class

NSAIDs
Oral Contraceptive
Gonadotropin Releasing Hormone
Others

By Route Of Administration

Oral
Injectable
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Endometriosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the endometriosis treatment market include Bayer AG, Pfizer Inc., AbbVie Inc, AstraZeneca, ObsEva SA, Teva Pharmaceutical Industries, Zydus Healthcare Limited, Eli Lilly and Company, Astellas Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ENDOMETRIOSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

6.1 Overview by Treatment Type
6.2 Historical and Forecast Data
6.3 Analysis by Treatment Type
6.4 Pain Medication Historic and Forecast Sales by Regions
6.5 Hormone Therapy Historic and Forecast Sales by Regions

7 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1 Overview by Drug Class
7.2 Historical and Forecast Data
7.3 Analysis by Drug Class
7.4 NSAIDs Historic and Forecast Sales by Regions
7.5 Oral Contraceptive Historic and Forecast Sales by Regions
7.6 Gonadotropin Releasing Hormone Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1 Overview by Route Of Administration
8.2 Historical and Forecast Data
8.3 Analysis by Route Of Administration
8.4 Oral Historic and Forecast Sales by Regions
8.5 Injectable Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
9.5 Retail Pharmacy Historic and Forecast Sales by Regions
9.6 Others Historic and Forecast Sales by Regions

10 . GLOBAL ENDOMETRIOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ENDOMETRIOSIS TREATMENT COMPANIES

11.1. Endometriosis Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF ENDOMETRIOSIS TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Bayer AG
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Pfizer Inc.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. AbbVie Inc
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. AstraZeneca
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. ObsEva SA
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Teva Pharmaceutical Industries
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Zydus Healthcare Limited
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Eli Lilly and Company
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Astellas Pharma Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表